Drug firm Claris Lifesciences today said USFDA inspectors have issued five observations highlighting violations of norms at its manufacturing facility at Chacharvadi-Vasna in Ahmedabad.
The company's wholly-owned subsidiary Claris Injectables had undergone an USFDA inspection, classified as prior approval inspection from August 16 to 26, 2016, on the plant 1 of its Chacharvadi-Vasna facility, Claris Lifesciences said in a filing to BSE.
"The company has received five 483s during the inspection and is confident to reply with in 15 days with corrective and preventive actions to address the same," it added.
The Form 483 notifies a company's management of objectionable conditions, which "may constitute violations" of norms in the judgement of the USFDA inspectors.
"Companies are encouraged to respond to the FDA Form 483 in writing with their corrective action plan and then implement that corrective action plan expeditiously," as per the United States Food and Drug Administration (USFDA) guidelines.
Disclaimer: No Business Standard Journalist was involved in creation of this content
